Published in J Virol on July 15, 2015
MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol (2013) 112.81
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Selforganization of matter and the evolution of biological macromolecules. Naturwissenschaften (1971) 13.09
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
HIV evolution: CTL escape mutation and reversion after transmission. Nat Med (2004) 10.21
Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell (1989) 9.66
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02
The accuracy of reverse transcriptase from HIV-1. Science (1988) 8.24
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science (1996) 7.73
Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature (2005) 6.78
HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions. J Acquir Immune Defic Syndr (1989) 6.16
Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol (1992) 6.09
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science (2000) 5.49
Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A (2011) 4.68
Evolutionary analysis of the dynamics of viral infectious disease. Nat Rev Genet (2009) 4.56
Origins of HIV and the AIDS pandemic. Cold Spring Harb Perspect Med (2011) 2.98
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
Reverse transcriptases and genomic variability: the accuracy of DNA replication is enzyme specific and sequence dependent. EMBO J (1990) 2.64
Evolvability of an RNA virus is determined by its mutational neighbourhood. Nature (2000) 2.32
Error catastrophe and antiviral strategy. Proc Natl Acad Sci U S A (2002) 2.10
Unfinished stories on viral quasispecies and Darwinian views of evolution. J Mol Biol (2010) 2.00
Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol (2006) 1.82
The role of mutational robustness in RNA virus evolution. Nat Rev Microbiol (2013) 1.54
Analysis of 454 sequencing error rate, error sources, and artifact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology (2013) 1.45
Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance. Proc Natl Acad Sci U S A (2011) 1.39
Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology (1994) 1.35
Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res (2014) 1.35
Codon usage determines the mutational robustness, evolutionary capacity, and virulence of an RNA virus. Cell Host Microbe (2012) 1.32
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog (2012) 1.30
Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog (2012) 1.28
HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions. Mol Biol Evol (2006) 1.10
The origin of hepatitis C virus. Curr Top Microbiol Immunol (2013) 1.07
Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. J Virol (2006) 1.06
Genotype 1 and global hepatitis C T-cell vaccines designed to optimize coverage of genetic diversity. J Gen Virol (2010) 1.05
Host-specific modulation of the selective constraints driving human immunodeficiency virus type 1 env gene evolution. J Virol (1999) 1.04
Next-generation sequencing of HIV-1 RNA genomes: determination of error rates and minimizing artificial recombination. PLoS One (2013) 1.04
Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy. J Infect Dis (2004) 1.04
Strong epistatic interactions within a single protein. Mol Biol Evol (2014) 0.95
Hepatitis C Virus (HCV) NS3 sequence diversity and antiviral resistance-associated variant frequency in HCV/HIV coinfection. Antimicrob Agents Chemother (2014) 0.94
Genetic and catalytic efficiency structure of an HCV protease quasispecies. Hepatology (2007) 0.93
Impact of highly active antiretroviral therapy on hepatitis C virus protease quasispecies diversity in HIV co-infected patients. J Med Virol (2010) 0.87
Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors. J Viral Hepat (2011) 0.87
New insights into the evolutionary rate of hepatitis B virus at different biological scales. J Virol (2015) 0.85
Trends for genetic variation of Hepatitis C Virus quasispecies in Human Immunodeficiency virus-1 coinfected patients. Virus Res (2007) 0.85
Impact of interferon-ribavirin treatment on hepatitis C virus (HCV) protease quasispecies diversity in HIV- and HCV-coinfected patients. J Infect Dis (2010) 0.81
Is hepatitis C virus NS3 protease quasispecies heterogeneity predictive of progression from cirrhosis to hepatocellular carcinoma? J Viral Hepat (2007) 0.78
Hepatitis C virus NS3/4A quasispecies diversity in acute hepatitis C infection in HIV-1 co-infected patients. J Viral Hepat (2014) 0.77
Synonymous Virus Genome Recoding as a Tool to Impact Viral Fitness. Trends Microbiol (2015) 0.78
Clinical Trials of Repurposed Antivirals for SARS-CoV-2. Antimicrob Agents Chemother (2020) 0.75